Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors
- 6 February 2019
- journal article
- review article
- Published by Springer Nature in Cancer Immunology, Immunotherapy
- Vol. 68 (3) , 341-352
Abstract
Immune checkpoint inhibitors (ICIs) targeting the programmed cell death-1 (PD-1)–programmed cell death ligand-1 (PD-L1) axis have shown promising results in non-small cell lung cancer (NSCLC) patients, some of them with persistent responses to these agents that form a population of long-term survivors. Despite the variable definition of PD-L1 positivity in tumors, an association between expression and response has been reasonably consistent in advanced NSCLC. In addition, the clinical efficacy of ICIs seems to be related to the genomic landscape of the tumor in terms of mutational burden and clonal neoantigens. Furthermore, increasing evidence shows that excessive activation of the immune response elicited by ICIs, leading to immune-related toxicities, might be associated with an improved response to immunotherapy. There are still many unanswered questions about the proper use of these agents to maximize their efficacy, which may be improved through combination with radiation, chemotherapy, targeted therapies, or other immune mediators, including dual checkpoint blockade. To search for clues for addressing these challenges, this review focused on the characteristics and clinical features of long-term NSCLC survivors and the potential biomarkers of response to ICIs.Keywords
Funding Information
- Bristol-Myers Squibb
This publication has 82 references indexed in Scilit:
- Spatial and temporal diversity in genomic instability processes defines lung cancer evolutionScience, 2014
- Extending Survival of Stage IV Non-Small Cell Lung CancerSeminars in Oncology, 2014
- Clinical factors predictive of long-term survival in advanced non-small cell lung cancerLung Cancer, 2013
- Genomic Landscape of Non-Small Cell Lung Cancer in Smokers and Never-SmokersCell, 2012
- The blockade of immune checkpoints in cancer immunotherapyNature Reviews Cancer, 2012
- Factors associated with long‐term survival of patients with advanced non‐small cell lung cancerRespirology, 2011
- Immune parameters affecting the efficacy of chemotherapeutic regimensNature Reviews Clinical Oncology, 2011
- Longs survivants de cancers bronchiques non à petites cellules stades IIIB-IV. Caractéristiques et facteurs pronostiques à partir d’une série rétrospectiveRevue des Maladies Respiratoires, 2009
- Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 BlockadeClinical Cancer Research, 2007
- Long-term survivors in stage IV non-small cell lung cancerLung Cancer, 2005